{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:17:10Z","timestamp":1780525030040,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"German Ministry of Economics and Technology","award":["AZ V-630-F-157-2012\/230"],"award-info":[{"award-number":["AZ V-630-F-157-2012\/230"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejpb.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T17:31:38Z","timestamp":1544031098000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Individualized in vitro and in silico methods for predicting in vivo performance of enteric-coated tablets containing a narrow therapeutic index drug"],"prefix":"10.1016","volume":"135","author":[{"given":"Frank","family":"Karkossa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.12.004_b0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1359-6446(04)03351-3","article-title":"Formulation strategies for absorption windows","volume":"10","author":"Davis","year":"2005","journal-title":"Drug. Discov. Today."},{"key":"10.1016\/j.ejpb.2018.12.004_b0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.P02.075","article-title":"Double-Blind study of an actively-transported levodopa prodrug, xp21279, in parkinson disease","volume":"80","author":"LeWitt","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejpb.2018.12.004_b0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2125.1986.tb05223.x","article-title":"Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution","volume":"21","author":"Lewis","year":"1986","journal-title":"Brit. J. Clin. Pharmaco."},{"key":"10.1016\/j.ejpb.2018.12.004_b0020","first-page":"67","article-title":"The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery","volume":"8","author":"Chen","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.12.004_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11095-005-8476-1","article-title":"Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability\/bioequivalence studies","volume":"23","author":"Kalantzi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.12.004_b0030","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejpb.2016.09.009","article-title":"Resolving the physiological conditions in bioavailability and bioequivalence studies: comparison of fasted and fed state","volume":"108","author":"Schneider","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2016.11.063","article-title":"Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities","volume":"519","author":"Hens","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2018.03.002","article-title":"Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water","volume":"127","author":"Grimm","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jps.24696","article-title":"Literature review of gastrointestinal physiology in the elderly, in pediatric patients, and in patients with gastrointestinal diseases","volume":"105","author":"Bai","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365521.2012.699548","article-title":"Gastrointestinal transit times and motility in patients with cystic fibrosis","volume":"47","author":"Hedsund","year":"2012","journal-title":"Scand. J. Gastroentero."},{"key":"10.1016\/j.ejpb.2018.12.004_b0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijpharm.2017.08.126","article-title":"A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson's disease","volume":"533","author":"Wollmer","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2013.10.006","article-title":"Paediatric oral biopharmaceutics: key considerations and current challenges","volume":"73","author":"Batchelor","year":"2014","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.ejpb.2018.12.004_b0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijpharm.2016.04.024","article-title":"Age-mediated changes in the gastrointestinal tract","volume":"512","author":"Merchant","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0075","unstructured":"Food and Drug Administration U.S. Department of Health and Human Services. FY2015 Regulatory Science Research Report: Narrow Therapeutic Index Drugs. https:\/\/www.fda.gov\/ForIndustry\/UserFees\/GenericDrugUserFees\/ucm500577.htm, 2012 (accessed 2017-06-29)."},{"key":"10.1016\/j.ejpb.2018.12.004_b0080","unstructured":"Health Canada. Guidance Document \u2013 Comparative Bioavilability Standards: Formulations used for Systemic Effects. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/comparative-bioavailability-standards-formulations-used-systemic-effects.html#a2.1.1.6, 2012 (accessed 2017-07-03)."},{"key":"10.1016\/j.ejpb.2018.12.004_b0085","unstructured":"Japan National Institute of Health Sciences, Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms, 2012, Pharmaceutical and Food Safety Bureau."},{"key":"10.1016\/j.ejpb.2018.12.004_b0090","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy \u2013 case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ejpb.2018.12.004_b0095","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.33.6.808","article-title":"Gastrointestinal tolerance of divalproex sodium","volume":"33","author":"Wilder","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.ejpb.2018.12.004_b0100","first-page":"435","article-title":"Propri\u00e9t\u00e9s pharmacodynamiques de l'acide n-dipropylac\u00e9tique","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.ejpb.2018.12.004_b0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt1977216736","article-title":"Pharmacokinetics and bioavailability of sodium valproate","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2018.12.004_b0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1528-1157.1980.tb04073.x","article-title":"Meal-dependent absorption of enteric-coated sodium valproate","volume":"21","author":"Levy","year":"1980","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2018.12.004_b0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","article-title":"The pharmacokinetics of valproic acid after oral and parenteral administration in healthy-volunteers","volume":"23","author":"Nitsche","year":"1982","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2018.12.004_b0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2125.1978.tb01713.x","article-title":"Pharmacokinetics of valproic acid after oral and intravenous administration","volume":"5","author":"Perucca","year":"1978","journal-title":"Brit. J. Clin. Pharmaco."},{"key":"10.1016\/j.ejpb.2018.12.004_b0130","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/jphp.12777","article-title":"Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets","volume":"69","author":"Karkossa","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.12.004_b0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.020","article-title":"A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds","volume":"51","author":"Garbacz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ijpharm.2014.09.003","article-title":"Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers","volume":"475","author":"Merchant","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1208\/s12249-013-9933-5","article-title":"An automated system for monitoring and regulating the pH of bicarbonate buffers","volume":"14","author":"Garbacz","year":"2013","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2018.12.004_b0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357056172","article-title":"Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model","volume":"57","author":"Klein","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.12.004_b0155","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2008.06.014","article-title":"Use of the BioDis to generate a physiologically relevant IVIVC","volume":"130","author":"Klein","year":"2008","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2018.12.004_b0160","first-page":"535","article-title":"Similar in vitro drug release as a surrogate of therapeutic equivalence of locally acting gastrointestinal products \u2013 what is the right in vitro method?","volume":"70","author":"Klein","year":"2015","journal-title":"Pharmazie."},{"key":"10.1016\/j.ejpb.2018.12.004_b0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1208\/s12249-016-0671-3","article-title":"Simulating different dosing scenarios for a child-appropriate valproate ER formulation in a new pediatric two-stage dissolution model","volume":"18","author":"Karkossa","year":"2017","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2018.12.004_b0170","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1002\/jps.24274","article-title":"Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap\u00ae system","volume":"104","author":"Koziolek","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0175","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.xphs.2018.02.016","article-title":"A biopredictive in vitro comparison of oral locally acting mesalazine formulations by a novel dissolution model for assessing intraluminal drug release in individual subjects","volume":"107","author":"Karkossa","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0939-6411(01)00134-5","article-title":"A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis","volume":"51","author":"Rudolph","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0185","first-page":"1118","article-title":"Bioavailability of a valproic acid preparation","volume":"36\u20132","author":"Hoffmann","year":"1986","journal-title":"Arzneimittel-Forsch."},{"key":"10.1016\/j.ejpb.2018.12.004_b0190","first-page":"1088","article-title":"[On the enteral absorption of valproic acid] Zur enteralen Resorption von Valproins\u00e4ure","volume":"27","author":"Oelkers","year":"1977","journal-title":"Arzneimittel-Forsch"},{"key":"10.1016\/j.ejpb.2018.12.004_b0195","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-198506000-00005","article-title":"Single-dose kinetics and bioavailability of sodium-hydrogen divalproate","volume":"8","author":"Anderson","year":"1985","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejpb.2018.12.004_b0200","series-title":"Biopharmaceutics Modeling and Simulations: Theory, Practice, Methods and Applications","author":"Sugano","year":"2012"},{"key":"10.1016\/j.ejpb.2018.12.004_b0205","unstructured":"RSC Publishing, The Merck Index, Cambridge, The Royal Society of Chemistry, 2013."},{"key":"10.1016\/j.ejpb.2018.12.004_b0210","unstructured":"Food and Drug Administration U.S. Department of Health and Human Services, Guidance for Industry: extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations, 1997."},{"key":"10.1016\/j.ejpb.2018.12.004_b0215","first-page":"502","article-title":"Factors affecting the dissolution rate of enteric coatings","volume":"39","author":"Spitael","year":"1977","journal-title":"Pharm. Ind."},{"key":"10.1016\/j.ejpb.2018.12.004_b0220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(93)90344-F","article-title":"An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting","volume":"91","author":"Ashford","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0225","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1023\/A:1016202814109","article-title":"Ionic strength dependence of dissolution for Eudragit S-100 coated pellets","volume":"12","author":"Kararli","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.12.004_b0230","doi-asserted-by":"crossref","first-page":"E668","DOI":"10.1208\/aapsj070367","article-title":"Anion-induced water flux as drug release mechanism through cationic Eudragit RS 30D film coatings","volume":"7","author":"Wagner","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2018.12.004_b0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0168-3659(02)00145-1","article-title":"Influence of chloride ion exchange on the permeability and drug release of Eudragit RS 30 D films","volume":"82","author":"Wagner","year":"2002","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2018.12.004_b0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1018910114436","article-title":"An organic acid-induced sigmoidal release system for oral controlled-release preparations","volume":"11","author":"Narisawa","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.12.004_b0245","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/js950180o","article-title":"An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid","volume":"85","author":"Narisawa","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0250","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1023\/A:1016021115481","article-title":"The influence of buffer species and strength on diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D","volume":"13","author":"Bodmeier","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.12.004_b0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejpb.2011.01.001","article-title":"Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products","volume":"78","author":"Liu","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0260","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1023\/A:1015937912504","article-title":"Kinetics of release from enteric-coated tablets","volume":"5","author":"Ozturk","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.12.004_b0265","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejps.2015.06.015","article-title":"Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms","volume":"77","author":"Wulff","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.12.004_b0270","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2014.04.019","article-title":"Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release","volume":"468","author":"Varum","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0275","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jconrel.2010.07.105","article-title":"A paradigm shift in enteric coating: achieving rapid release in the proximal small intestine of man","volume":"147","author":"Liu","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2018.12.004_b0280","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.ejpb.2013.09.009","article-title":"Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac","volume":"85","author":"Kambayashi","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.12.004_b0285","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejpb.2008.05.029","article-title":"Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses","volume":"70","author":"Garbacz","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118310634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118310634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T01:40:43Z","timestamp":1720834843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118310634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":57,"alternative-id":["S0939641118310634"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.12.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized in vitro and in silico methods for predicting in vivo performance of enteric-coated tablets containing a narrow therapeutic index drug","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}